While riding high on the popularity of its weight loss drug Zepbound, the company is quietly building a presence in a cutting ...

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025 ...

COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk warned on Tuesday ‌that ​profits and sales could drop ‌as much as 13% this year, the first declines in years, in a ​new setback for the obesity ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

Eli Lilly plans to build a $3.5 billion pharmaceutical plant in Upper Macungie Township, for its next-generation weight-loss ...

Eli Lilly is scheduled to report its fourth-quarter results before the market opens Wednesday. Here is what you need to know. PROFIT: Analysts polled by FactSet expect the company to post net income ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Eli Lilly and Co. has announced $50 billion in U.S. expansion commitments since 2020, including numerous manufacturing plants ...

We sold the Lilly team on our ability to move quickly and to deliver speed to market,” Shapiro said. “We are the fastest around.” ...

For full-year 2025, sales are projected at DKK 307.62B, up from DKK 290.4B in 2024, with Wegovy contributing DKK 78.28B and Ozempic DKK 124.87B. EPS is forecast at DKK 23.28, compared with DKK 22.63 ...

Lilly has also signaled that seven more Phase 3 trials for retatrutide are expected to conclude in 2026, making it a pivotal ...

Management reported that the facility would bring 850 high-value jobs to the region, including scientists, engineers, lab ...